MTOR and Decreased total leukocyte count: Combination therapy with CDK4/6 and mTOR inhibitors could also enable the use of lower doses, thus diminishing adverse effects and toxicity in patients, as neutropenia, leukopenia, thrombocytopenia, anemia, fatigue or diarrhea.